Literature DB >> 8798108

Plasma endothelin in congestive heart failure: a predictor of cardiac death?

S Galatius-Jensen1, H Wroblewski, C Emmeluth, P Bie, S Haunsø, J Kastrup.   

Abstract

BACKGROUND: Endothelin is a potent vasoconstrictor, with growth-promoting and possible cardiotoxic and arrhythmogenic properties. This study investigates the association between increased plasma endothelin in congestive heart failure and prognosis. METHODS AND
RESULTS: Forty-four patients with congestive heart failure showed increased plasma endothelin concentrations (mean +/- SD, 3.7 +/- 1.7 pg/mL; n = 44) compared with healthy volunteers (2.0 +/- 0.4 pg/mL, n = 21, P < .00003). Plasma endothelin increased with the severity of the disease. All patients were followed for an average of 17 months (range, 2-25 months). Cardiac mortality was 27% (8 of 30 patients) in the group with plasma endothelin concentrations above 3 pg/mL and 0% (0 of 14 patients) in the group with plasma endothelin concentrations below 3 pg/mL (P < .05). In contrast, separation of patients based on different New York Heart Association groups and ejection fractions revealed no significant difference regarding this endpoint.
CONCLUSIONS: Increased plasma endothelin concentrations in patients with congestive heart failure appears to serve as a predictor of cardiac death.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8798108     DOI: 10.1016/s1071-9164(96)80025-x

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  13 in total

Review 1.  Heart failure in 10 years time: focus on pharmacological treatment.

Authors:  J J V McMurray
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

Review 2.  Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure.

Authors:  H Krum; R Denver; A Tzanidis; P Martin
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 3.  Endothelin receptor antagonists and cardiovascular diseases of aging.

Authors:  M P Love; J J McMurray
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 4.  Endothelin in heart failure.

Authors:  G Sütsch; M Barton
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

Review 5.  Drug therapy in chronic heart failure.

Authors:  D B McKenzie; A J Cowley
Journal:  Postgrad Med J       Date:  2003-11       Impact factor: 2.401

Review 6.  Insights into pathogenesis and treatment of cytokines in cardiomyopathy.

Authors:  L Vadlamani; W T Abraham
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 3.955

7.  Identification of persons with cardiorespiratory conditions who are at risk of dying from the acute effects of ambient air particles.

Authors:  M S Goldberg; R T Burnett; J C Bailar; R Tamblyn; P Ernst; K Flegel; J Brook; Y Bonvalot; R Singh; M F Valois; R Vincent
Journal:  Environ Health Perspect       Date:  2001-08       Impact factor: 9.031

8.  Correlation between Saliva and Plasma Levels of Endothelin Isoforms ET-1, ET-2, and ET-3.

Authors:  Roma Gurusankar; Prem Kumarathasan; Anusha Saravanamuthu; Errol M Thomson; Renaud Vincent
Journal:  Int J Pept       Date:  2015-04-20

9.  Toxicogenomic analysis of susceptibility to inhaled urban particulate matter in mice with chronic lung inflammation.

Authors:  Errol M Thomson; Andrew Williams; Carole L Yauk; Renaud Vincent
Journal:  Part Fibre Toxicol       Date:  2009-03-11       Impact factor: 9.400

Review 10.  Potential role of ultrafine particles in associations between airborne particle mass and cardiovascular health.

Authors:  Ralph J Delfino; Constantinos Sioutas; Shaista Malik
Journal:  Environ Health Perspect       Date:  2005-08       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.